Ignet

Gene Information

Gene symbol: HMHA1

Gene name: histocompatibility (minor) HA-1

HGNC ID: 17102

Synonyms: KIAA0223, HA-1, ARHGAP45

Related Genes

#	Gene Symbol	Number of hits
1	CD4	1 hits
2	CLEC7A	1 hits
3	F12	1 hits
4	HLA-A	1 hits
5	IL4	1 hits
6	KRT31	1 hits
7	MYO1G	1 hits
8	PRTN3	1 hits
9	RUNX1T1	1 hits
10	XIAP	1 hits

Related Sentences

#	PMID	Sentence
1	1379424	Four linear synthetic peptides corresponding to residues 12-29, 50-67, 121-138 and 131-147 of the HA 1 subunit of H3 subtype influenza virus (NT/60/68) were tested for their capacity to elicit in vivo peptide-specific CD4+ T cells cross reacting with whole virus.
2	15000488	The first clinical application of the hematopoietic minor histocompatibility antigens HA-1 and HA-2 is currently being explored in a stem cell-based setting for hematologic malignancies.
3	16707472	For minor histocompatibility antigens HA-1 and HA-2, normal cell expression is restricted to hemopoietic cells, and boosting the immune response to these antigens may potentiate graft-versus-leukemia effect without accompanying graft-versus-host disease.
4	16707472	To increase efficacy, expansion of HA-1- or HA-2-specific CTL before transplantation is desirable.
5	16707472	However, primary HA-1- or HA-2-specific CTL expanded in vitro are often of low avidity.
6	16707472	For clinical application, we constructed vaccines encoding HLA-A0201-restricted peptides from human HA-1 and HA-2, which were fused to DOM, and tested their performance in HLA-A0201-transgenic mice.
7	16707472	Strikingly, these mouse T cells efficiently killed human lymphoblastoid cell lines expressing endogenous HA-1 or HA-2.
8	16707472	High avidity is indicated by the independence of cytolysis from CD8/MHC class I interaction.
9	16707472	These safe epitope-specific vaccines offer a potential strategy to prime HA-1- or HA-2-specific CTL in transplant donors before adoptive transfer.
10	16707472	For minor histocompatibility antigens HA-1 and HA-2, normal cell expression is restricted to hemopoietic cells, and boosting the immune response to these antigens may potentiate graft-versus-leukemia effect without accompanying graft-versus-host disease.
11	16707472	To increase efficacy, expansion of HA-1- or HA-2-specific CTL before transplantation is desirable.
12	16707472	However, primary HA-1- or HA-2-specific CTL expanded in vitro are often of low avidity.
13	16707472	For clinical application, we constructed vaccines encoding HLA-A0201-restricted peptides from human HA-1 and HA-2, which were fused to DOM, and tested their performance in HLA-A0201-transgenic mice.
14	16707472	Strikingly, these mouse T cells efficiently killed human lymphoblastoid cell lines expressing endogenous HA-1 or HA-2.
15	16707472	High avidity is indicated by the independence of cytolysis from CD8/MHC class I interaction.
16	16707472	These safe epitope-specific vaccines offer a potential strategy to prime HA-1- or HA-2-specific CTL in transplant donors before adoptive transfer.
17	16707472	For minor histocompatibility antigens HA-1 and HA-2, normal cell expression is restricted to hemopoietic cells, and boosting the immune response to these antigens may potentiate graft-versus-leukemia effect without accompanying graft-versus-host disease.
18	16707472	To increase efficacy, expansion of HA-1- or HA-2-specific CTL before transplantation is desirable.
19	16707472	However, primary HA-1- or HA-2-specific CTL expanded in vitro are often of low avidity.
20	16707472	For clinical application, we constructed vaccines encoding HLA-A0201-restricted peptides from human HA-1 and HA-2, which were fused to DOM, and tested their performance in HLA-A0201-transgenic mice.
21	16707472	Strikingly, these mouse T cells efficiently killed human lymphoblastoid cell lines expressing endogenous HA-1 or HA-2.
22	16707472	High avidity is indicated by the independence of cytolysis from CD8/MHC class I interaction.
23	16707472	These safe epitope-specific vaccines offer a potential strategy to prime HA-1- or HA-2-specific CTL in transplant donors before adoptive transfer.
24	16707472	For minor histocompatibility antigens HA-1 and HA-2, normal cell expression is restricted to hemopoietic cells, and boosting the immune response to these antigens may potentiate graft-versus-leukemia effect without accompanying graft-versus-host disease.
25	16707472	To increase efficacy, expansion of HA-1- or HA-2-specific CTL before transplantation is desirable.
26	16707472	However, primary HA-1- or HA-2-specific CTL expanded in vitro are often of low avidity.
27	16707472	For clinical application, we constructed vaccines encoding HLA-A0201-restricted peptides from human HA-1 and HA-2, which were fused to DOM, and tested their performance in HLA-A0201-transgenic mice.
28	16707472	Strikingly, these mouse T cells efficiently killed human lymphoblastoid cell lines expressing endogenous HA-1 or HA-2.
29	16707472	High avidity is indicated by the independence of cytolysis from CD8/MHC class I interaction.
30	16707472	These safe epitope-specific vaccines offer a potential strategy to prime HA-1- or HA-2-specific CTL in transplant donors before adoptive transfer.
31	16707472	For minor histocompatibility antigens HA-1 and HA-2, normal cell expression is restricted to hemopoietic cells, and boosting the immune response to these antigens may potentiate graft-versus-leukemia effect without accompanying graft-versus-host disease.
32	16707472	To increase efficacy, expansion of HA-1- or HA-2-specific CTL before transplantation is desirable.
33	16707472	However, primary HA-1- or HA-2-specific CTL expanded in vitro are often of low avidity.
34	16707472	For clinical application, we constructed vaccines encoding HLA-A0201-restricted peptides from human HA-1 and HA-2, which were fused to DOM, and tested their performance in HLA-A0201-transgenic mice.
35	16707472	Strikingly, these mouse T cells efficiently killed human lymphoblastoid cell lines expressing endogenous HA-1 or HA-2.
36	16707472	High avidity is indicated by the independence of cytolysis from CD8/MHC class I interaction.
37	16707472	These safe epitope-specific vaccines offer a potential strategy to prime HA-1- or HA-2-specific CTL in transplant donors before adoptive transfer.
38	16707472	For minor histocompatibility antigens HA-1 and HA-2, normal cell expression is restricted to hemopoietic cells, and boosting the immune response to these antigens may potentiate graft-versus-leukemia effect without accompanying graft-versus-host disease.
39	16707472	To increase efficacy, expansion of HA-1- or HA-2-specific CTL before transplantation is desirable.
40	16707472	However, primary HA-1- or HA-2-specific CTL expanded in vitro are often of low avidity.
41	16707472	For clinical application, we constructed vaccines encoding HLA-A0201-restricted peptides from human HA-1 and HA-2, which were fused to DOM, and tested their performance in HLA-A0201-transgenic mice.
42	16707472	Strikingly, these mouse T cells efficiently killed human lymphoblastoid cell lines expressing endogenous HA-1 or HA-2.
43	16707472	High avidity is indicated by the independence of cytolysis from CD8/MHC class I interaction.
44	16707472	These safe epitope-specific vaccines offer a potential strategy to prime HA-1- or HA-2-specific CTL in transplant donors before adoptive transfer.
45	18790448	These strategies include the use of vaccines against minor histocompatibility antigens (HA-1, HA-2 and H-Y) and leukaemia-specific antigens (proteinase 3, Wilms' tumour 1 and BCR-ABL), and the adoptive transfer of leukaemia-specific T cells.
46	21110118	In this study, highly pure recombinant proteins generated using baculovirus expression vector system based on full-length of HA (HAF) and antigenic region of HA(1) genes of H9 subtype, and also inactivated whole virus were used to immunization of chickens.
47	21110118	Relative to the conventional method using whole virus immunization and recombinant HAF protein, the antiserum prepared by recombinant HA(1) had a specificity of 100% for all tested subtypes.
48	21110118	In this study, highly pure recombinant proteins generated using baculovirus expression vector system based on full-length of HA (HAF) and antigenic region of HA(1) genes of H9 subtype, and also inactivated whole virus were used to immunization of chickens.
49	21110118	Relative to the conventional method using whole virus immunization and recombinant HAF protein, the antiserum prepared by recombinant HA(1) had a specificity of 100% for all tested subtypes.
50	21406268	Passages of these viruses on Vero cells led to the appearance of single mutations in the HA(1) L194P or HA(2) G75R subunits that impaired virus stability.
51	22131355	The results showed that both LA4356-pH and DLD17-pH could significantly increase the specific anti-HA(1) IgA antibody level in the mucosa and the anti-HA(1) IgG level in serum, as well as stimulating the splenic lymphocyte proliferative reaction through increased expression of interleukin-4 (IL-4).
52	23956116	Minor histocompatibility antigen HA-1-specific cytotoxic lymphocyte (CTL) clones have apparent anti-leukaemic efficacy, and the AML/ETO gene is a special fusion gene in leukaemic cells.
53	23956116	Thus, we hypothesised that a vaccine targeting HA-1 and AML/ETO could stimulate NK cells to target leukaemia cells.
54	23956116	The level of miR-182, which targets ULBP2, significantly decreased with increasing IFN-γ and granzyme B in a co-recombinant group.
55	23956116	In summary, DNA vaccines including AML/ETO and HA-1 fragments significantly enhance the innate immunity of NK cells in vitro.
56	23956116	Minor histocompatibility antigen HA-1-specific cytotoxic lymphocyte (CTL) clones have apparent anti-leukaemic efficacy, and the AML/ETO gene is a special fusion gene in leukaemic cells.
57	23956116	Thus, we hypothesised that a vaccine targeting HA-1 and AML/ETO could stimulate NK cells to target leukaemia cells.
58	23956116	The level of miR-182, which targets ULBP2, significantly decreased with increasing IFN-γ and granzyme B in a co-recombinant group.
59	23956116	In summary, DNA vaccines including AML/ETO and HA-1 fragments significantly enhance the innate immunity of NK cells in vitro.
60	23956116	Minor histocompatibility antigen HA-1-specific cytotoxic lymphocyte (CTL) clones have apparent anti-leukaemic efficacy, and the AML/ETO gene is a special fusion gene in leukaemic cells.
61	23956116	Thus, we hypothesised that a vaccine targeting HA-1 and AML/ETO could stimulate NK cells to target leukaemia cells.
62	23956116	The level of miR-182, which targets ULBP2, significantly decreased with increasing IFN-γ and granzyme B in a co-recombinant group.
63	23956116	In summary, DNA vaccines including AML/ETO and HA-1 fragments significantly enhance the innate immunity of NK cells in vitro.
64	24810638	Our culture protocol generated a clinically relevant number of mature CD1a myeloid DC and CD207 Langerhans cells (LC)-like DC subsets from CD34 HPC with >95% purity.
65	24810638	Additional studies revealed that UCC-DC and UCB-LC can efficiently expand minor histocompatibility antigen (MiHA) HA-1-specific cytotoxic T cells in the peripheral blood of leukemia patients and prime MiHA HA-1-specific and HA-2-specific cytotoxic T cells in vitro.
66	24835401	To study this, we employed an in vitro system in which influenza hemagglutinin (HA) 1 was delivered to dendritic cells (DCs) via Dectin-1 using anti-human Dectin-1 (hDectin-1)-HA1 recombinant fusion proteins.
67	24835401	Nonetheless, these DCs were not able to induce a significant level of HA1-specific Th17 responses even in the presence of the Th17-promoting cytokines IL-1β and IL-6.
68	24835401	Thus, interruptions in STAT3 or MyD88 signaling led to substantially diminished HA1-specific Th17 induction.